01—Abstract
Summary
Summary of the 10-K filed February 28, 2017. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies.
Its business rests on two pillars: developing proprietary products, led by PEGPH20 in oncology, and licensing its rHuPH20 enzyme platform (ENHANZE Technology) to biopharmaceutical partners. Its approved product, Hylenex recombinant, is sold in the U.S. through a distributor. The company reported total revenues of $146,691 thousanda for 2016, up from $135,057 thousand in 2015, while net loss widened to $103,023 thousand from $32,231 thousand.
Royalty revenue rose to $50,984 thousandb, and Roche accounted for 63% of total revenues in 2016. The central near-term event in the filing is the January 2017 topline announcement of combined Stage 1 and Stage 2 results for Study 109-202 of PEGPH20 with ABRAXANE and gemcitabine in stage IV pancreatic ductal adenocarcinoma. In the 84 HA-High patients, median progression-free survival was 9.2 months in the PEGPH20 arm versus 5.2 months in the control arm (HR 0.51, p=0.048).
The overall study population's primary PFS endpoint was also met with statistical significance (6.0 vs. 5.3 months, p=0.048). The exploratory overall survival result was 11.5 vs. 8.5 months, and the filing notes that about 40%c of patients in the PEGPH20 arm discontinued treatment at the time of a 2014 clinical hold. A Phase 3 study (109-301) is ongoing.
Financially, the company ended 2016 with cash, cash equivalents and marketable securities of $204,981 thousandd, up from $108,339 thousand, primarily due to a $150 million royalty-backed loan from January 2016 and a $55.0 million senior secured loan from June 2016. Stockholders' equity moved to a deficit of $(32,481) thousand from $42,999 thousand. The company states that current cash is sufficient to fund operations for at least the next twelve months, and it has accumulated net losses of approximately $585.3 million through December 31, 2016.
02—Key points
Key Highlights
- Total revenues were $146,691 thousand in 2016, compared with $135,057 thousand in 2015 and $75,334 thousand in 2014.
- Net loss was $103,023 thousand ($0.81 per share) in 2016, compared with $32,231 thousand in 2015, as R&D expense rose to $150,842 thousand from $93,236 thousand.
- Royalty revenue was $51.0 million in 2016, up from $31.0 million in 2015, driven by Herceptin SC, MabThera SC and HYQVIA sales.
- In January 2017, Study 109-202 showed a median PFS of 9.2 months versus 5.2 months in HA-High patients (HR 0.51, p=0.048); the primary PFS endpoint in the overall efficacy-evaluable population was also met (6.0 vs. 5.3 months, p=0.048).
- The Phase 3 Study 109-301 of PEGPH20 in stage IV PDA was ongoing, with the first patient dosed in March 2016 and initiation at 85% of global sites by January 2017.
- Cash, cash equivalents and marketable securities totaled $204,981 thousand at year-end 2016, supported by a $150 million royalty-backed loan and a $55.0 million Oxford/SVB facility.
- Roche accounted for 63% of 2016 total revenues, and long-term debt, net increased to $199,228 thousand from $27,971 thousand.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2016, Halozyme Therapeutics lost $0.70.
- Revenue$146.7M100.0%
- Cost of revenue−$33.2M22.6%
- Gross profit$113.5M77.4%
- Operating costs−$196.7M134.1%
- Operating income−$83.2M56.7%
- Interest, other & tax−$19.8M13.5%
- Net income−$103.0M70.2%
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 28, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $146.69M$135.06M | +8.6% |
| Cost of Revenue | $33.21M$29.25M | +13.5% |
| Gross Profit | $113.48M$105.81M | +7.3% |
| R&D Expenses | $150.84M$93.24M | +61.8% |
| SG&A Expenses | $45.85M$40.03M | +14.6% |
| Operating Expenses | $229.90M$162.51M | +41.5% |
| Operating Income | -$83.21M-$27.45M | −203.1% |
| Interest Expense | $19.98M$5.20M | +284.1% |
| Net Income | -$103.02M-$32.23M | −219.6% |
| EPS (Basic) | $-0.81$-0.25 | −224.0% |
| EPS (Diluted) | $-0.81$-0.25 | −224.0% |
| Shares Outstanding (Basic) | 127.96M126.70M | +1.0% |
| Shares Outstanding (Diluted) | 127.96M126.70M | +1.0% |
05—Questions
Frequently Asked Questions
What drove the increase in Halozyme's 2016 revenue?
Total revenues rose to $146,691 thousand from $135,057 thousand. Royalties increased to $50,984 thousand from $30,975 thousand on higher Roche and Baxalta collaboration product sales, and product sales, net rose to $53,392 thousand from $46,082 thousand, mainly from bulk rHuPH20 sales to Baxalta and Roche. Revenues under collaborative agreements fell to $42,315 thousand from $58,000 thousand, because 2015 included $25.0 million from Lilly and $23.0 million from AbbVie license fees.
What were the key results from the January 2017 PEGPH20 pancreatic cancer announcement?
In the combined Stage 1 and Stage 2 analysis of Study 109-202, the primary PFS endpoint in the 231-patient efficacy-evaluable population was met with a median of 6.0 months versus 5.3 months (HR 0.73, p=0.048). In the 84 HA-High patients, median PFS was 9.2 months versus 5.2 months (HR 0.51, p=0.048). The exploratory median OS was 11.5 months versus 8.5 months. The filing notes that many PEGPH20-arm patients discontinued treatment at the 2014 clinical hold, which may affect these results.
Why did the company's cash position improve despite a larger net loss?
Cash, cash equivalents and marketable securities rose to $204,981 thousand from $108,339 thousand. Net cash provided by financing activities was $150,621 thousand, including net proceeds of $148.0 million from the Royalty-backed Loan and $55.0 million from the new Oxford and SVB Loan, partly offset by a $54.3 million repayment of the previous loan. Net cash used in operations increased to $50,383 thousand from $37,083 thousand.
Does the company expect its current cash to be sufficient?
The filing states that current cash, cash equivalents and marketable securities are believed to be sufficient to fund operations for at least the next twelve months. It also says existing resources may not be adequate to fund operations until the company becomes profitable, if ever, and that it will likely need to raise additional capital in the future.
What are the main risks to the company's debt obligations?
The Royalty-backed Loan is repaid from specified royalty payments from Roche and Baxalta, and its balance was $161.8 million at December 31, 2016, including $13.2 million of payment-in-kind interest. The New Loan Agreement carried an outstanding balance of $54.8 million. Both agreements contain covenants and events of default, and an event of default could allow lenders to accelerate repayment.
06—Continue